DNMT1 and acute myeloid leukemia: Studies have demonstrated that DNMT inhibitors can upregulate the expression of target antigens such as CD33 or CD123 on the surface of AML cells, thereby increasing the binding affinity and cytotoxicity of antibody-based therapies (Zeng et al., 2024).